CTCs‐derived xenograft development in a triple negative breast cancer case

• DOI: 10.1002/ijc.32001
• Publication Date: 2018-11-19T08:44:43Z
• Authors: Tais Pereira‐Veiga; Manuel Abreu; Diego Robledo; Xavier Matias‐Guiu; María Santacana; Laura Sánchez; Juan Cueva; Patricia Palacios; Ihab Abdulkader; Rafael López‐López; Laura Muinelo‐Romay; Clotilde Costa
• Keywords: Triple-negative breast cancer; Circulating tumor cell

Triple‐negative breast cancer (TNBC) is characterized by high rates of metastasis and no available molecular targets. CTCs derived xenografts (CDX) have demonstrated to be a promising tool for understanding biology. In our study, CDX from TNBC patient was developed the first time. After characterization, WNT signaling found as main mechanism related with this tumor biology potential markers were identified subsequently validated in patients. cohort levels MELK expression associated poorer survival rates. Overall, study demonstrates that are tumorigenic CDXs useful model obtain valuable information about tumor.